{"id":"W2915708315","doi":"10.1200/jco.18.01998","title":"Evaluation of Two Dosing Regimens for Nivolumab in Combination With Ipilimumab in Patients With Advanced Melanoma: Results From the Phase IIIb/IV CheckMate 511 Trial","year":2019,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Cancer Immunotherapy and Biomarkers","field":"Medicine","cited_by":398,"is_retracted":false,"has_abstract":true,"ca_institutions":"Alberta Cancer Foundation","funders":"Bristol-Myers Squibb","keywords":"Medicine; Ipilimumab; Nivolumab; Dosing; Oncology; Melanoma; Internal medicine; Metastatic melanoma; Clinical trial; Cancer; Immunotherapy; Cancer research","routes":{"ca_aff":true,"ca_fund":false,"ca_venue":false,"about_ca":false,"invisible_to_affiliation_only":false},"retraction":null,"screen":null,"direct_labels":[],"prediction":{"model_version":"metacan-v3-hybrid-931329e0061c","candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.001829458,0.001107414,0.001690869,0.0004145885,0.0003718226,0.001113529,0.0008862465,0.001413528,0.00295478],"category_scores_gemma":[0.001331933,0.0004795211,0.001430537,0.0003119394,0.000670786,0.0007799823,0.0002796396,0.003061267,0.0006568845],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.001141977,"about_ca_system_score_gemma":0.001022413,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.0008620815,"about_ca_topic_score_gemma":0.00181439,"domain_scores_codex":[0.9994656,0.0002610492,0.00003638041,0.00009428455,0.00006362539,0.00007908882],"domain_scores_gemma":[0.9992476,0.0001782869,0.000191845,0.00007086881,0.00003759039,0.0002737349],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","study_design_scores_codex":[0.8065414,0.05302755,0.004624936,0.0008132997,0.001770688,0.0001052552,0.0002063619,0.002336764,0.0184446,0.0001829205,0.002371103,0.1095751],"study_design_scores_gemma":[0.6332871,0.3513014,0.009340328,0.00005176536,0.0007035146,0.0001259916,0.00003718268,0.00130889,0.002039346,0.0001169444,0.001656714,0.00003078792],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","genre_codex":"empirical","genre_gemma":"empirical","genre_scores_codex":[0.9938821,0.00298258,0.000298136,0.0003547469,0.0001252309,0.0008371404,0.0003860397,0.00005034885,0.001083782],"genre_scores_gemma":[0.9938915,0.001477419,0.0007741455,0.0007043985,0.000151218,0.0008488565,0.0008580622,0.00001898621,0.001275414],"genre_candidate":"empirical","genre_consensus":"empirical","teacher_disagreement_score":0.00295478,"threshold_uncertainty_score":0.009884715,"prediction_status":"machine_predicted_unvalidated"},"machine_scores":{"provisional":true,"baseline":true,"maturity_gate_passed":false,"score_opus":0.09565285910935743,"score_gpt":0.4600113664279852,"score_spread":0.3643585073186277,"validation_status":"score_only:v0-immature-baseline","note":"Baseline scores from an immature model (maturity gate not passed). Scores rank; they never assert a category."}}